Tema Etfs LLC bought a new position in Exelixis, Inc. (NASDAQ:EXEL - Free Report) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 49,256 shares of the biotechnology company's stock, valued at approximately $1,640,000.
Other institutional investors and hedge funds have also bought and sold shares of the company. Blue Trust Inc. increased its holdings in shares of Exelixis by 134.7% in the 4th quarter. Blue Trust Inc. now owns 14,302 shares of the biotechnology company's stock worth $476,000 after buying an additional 8,208 shares during the last quarter. Raymond James Financial Inc. purchased a new position in Exelixis in the fourth quarter worth $17,046,000. Allspring Global Investments Holdings LLC increased its stake in Exelixis by 82.1% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 1,562,790 shares of the biotechnology company's stock valued at $52,884,000 after acquiring an additional 704,786 shares during the last quarter. Inspire Investing LLC raised its position in Exelixis by 25.0% during the fourth quarter. Inspire Investing LLC now owns 36,659 shares of the biotechnology company's stock valued at $1,221,000 after purchasing an additional 7,331 shares in the last quarter. Finally, Robeco Institutional Asset Management B.V. raised its position in Exelixis by 4.6% during the fourth quarter. Robeco Institutional Asset Management B.V. now owns 505,289 shares of the biotechnology company's stock valued at $16,826,000 after purchasing an additional 22,225 shares in the last quarter. 85.27% of the stock is owned by hedge funds and other institutional investors.
Analyst Ratings Changes
A number of equities analysts have recently issued reports on EXEL shares. JMP Securities reiterated a "market outperform" rating and issued a $41.00 price objective on shares of Exelixis in a report on Thursday, April 17th. Morgan Stanley reaffirmed an "overweight" rating and issued a $47.00 target price (up previously from $40.00) on shares of Exelixis in a research note on Wednesday, May 14th. Piper Sandler lifted their price target on shares of Exelixis from $37.00 to $38.00 and gave the stock an "overweight" rating in a research note on Wednesday, February 12th. Barclays lifted their price objective on Exelixis from $25.00 to $29.00 and gave the stock an "equal weight" rating in a research report on Thursday, February 13th. Finally, Royal Bank of Canada restated an "outperform" rating and set a $40.00 target price on shares of Exelixis in a report on Wednesday, May 14th. Two research analysts have rated the stock with a sell rating, six have assigned a hold rating and twelve have given a buy rating to the stock. According to data from MarketBeat.com, Exelixis has a consensus rating of "Moderate Buy" and an average price target of $38.94.
View Our Latest Stock Analysis on Exelixis
Exelixis Price Performance
NASDAQ:EXEL traded down $0.64 during mid-day trading on Wednesday, hitting $43.72. 2,982,743 shares of the company's stock were exchanged, compared to its average volume of 2,289,628. The company has a market cap of $11.92 billion, a PE ratio of 24.70, a P/E/G ratio of 1.13 and a beta of 0.25. Exelixis, Inc. has a one year low of $20.14 and a one year high of $48.85. The business has a fifty day moving average price of $37.54 and a 200 day moving average price of $35.97.
Insider Buying and Selling at Exelixis
In other news, EVP Patrick J. Haley sold 126,383 shares of the firm's stock in a transaction dated Thursday, May 15th. The shares were sold at an average price of $47.96, for a total transaction of $6,061,328.68. Following the sale, the executive vice president now owns 446,459 shares of the company's stock, valued at $21,412,173.64. This trade represents a 22.06% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Christopher J. Senner sold 29,314 shares of Exelixis stock in a transaction that occurred on Monday, February 24th. The stock was sold at an average price of $36.14, for a total transaction of $1,059,407.96. Following the completion of the sale, the chief financial officer now directly owns 779,607 shares of the company's stock, valued at approximately $28,174,996.98. This trade represents a 3.62% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 520,942 shares of company stock valued at $22,930,002. Corporate insiders own 2.82% of the company's stock.
About Exelixis
(
Free Report)
Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.
Further Reading
Before you consider Exelixis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Exelixis wasn't on the list.
While Exelixis currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
